Brandon Capital

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapeutics. The company specializes in alpha-emitting isotopes that are linked to molecules designed to deliver targeted cytotoxic radiation directly to tumors. This approach allows for radiotherapy at the molecular level, addressing significant challenges in targeted alpha therapy, particularly in ensuring a reliable and scalable supply. AdvanCell aims to provide safe and effective treatment options for various forms of cancer, with the goal of establishing its therapies as a standard of care in oncology.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Pheon Therapeutics is a London-based biotechnology company specializing in the development of Antibody-Drug Conjugates (ADCs) for challenging cancer types. Founded in 2022, the company focuses on creating a novel pipeline of next-generation ADCs designed to target solid tumors that are often resistant to existing treatments. Its lead program features a first-in-class ADC aimed at a unique target that is highly expressed in various hard-to-treat cancers. By advancing these innovative therapies, Pheon Therapeutics aims to provide effective treatment options for patients and healthcare providers facing the complexities of cancer management.

Currus Biologics is a biotechnology company focused on developing CAR-T cell therapies specifically aimed at treating solid tumor cancers. The company specializes in creating bispecific antigen-presenting and T-cell engagers to target and combat various cancer types, including breast, colon, pancreatic, and prostate cancers. By designing chimeric antigen receptors that can effectively kill cancer cells, Currus Biologics aims to provide innovative treatment solutions for patients with solid tumor indications.

PolyActiva is a biotechnology company specializing in the development of proprietary drug-polymer conjugate technology aimed at site-specific drug delivery. The company's innovative delivery platform is designed to facilitate the administration of therapeutic doses over extended periods from various medical device components, including ocular implants, intra-articular gel implants, and drug-eluting fibers. By creating biodegradable implants that sustain drug release, PolyActiva enhances patient outcomes and quality of life, particularly for individuals suffering from ophthalmic diseases such as glaucoma. This technology empowers healthcare organizations to provide more effective drug treatments tailored to the needs of patients.

Respirion Pharmaceuticals is an early-stage biotechnology company established in 2018, specializing in the development of innovative treatments for respiratory diseases. Originating as a spinout from the Telethon Kids Institute in Perth, the company focuses on addressing life-threatening conditions such as Cystic Fibrosis. Its leading product is an inhaled therapy that combines the antibiotic tobramycin with an adjuvant, designed to disrupt bacterial biofilms in the lungs, thereby enhancing the efficacy of antibiotic treatment and improving patient outcomes. Promising results from early clinical studies conducted in collaboration with the Western Australian Department of Health have paved the way for further research. To advance its clinical trials, Respirion has formed partnerships with significant organizations, including Australia’s Medical Research Commercialisation Fund and the US Cystic Fibrosis Foundation, aiming to expand its impact in both Australia and the United States.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Pathios Therapeutics is an early-stage biotech company based in Oxford, United Kingdom, focused on developing therapies for autoimmune diseases and cancer. Founded in 2017, the company specializes in creating small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to counteract the immunosuppressive effects of immune cells, such as tumor-associated macrophages, which are influenced by the acidic environment often found in tumors. By leveraging a deep scientific approach and human genetic insights, Pathios Therapeutics aims to generate novel therapeutics for advanced solid tumors and other unmet medical needs.

AstronauTx is a biotechnology company focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative conditions. The company specializes in restoring the normal function of astrocytes, which are crucial for supporting neuronal activity and maintaining brain health. In healthy individuals, astrocytes play a vital role in metabolism and the integrity of the blood-brain barrier; however, in neurodegenerative diseases, their dysfunction can contribute to neurotoxicity. By targeting these processes, AstronauTx aims to enable healthcare professionals to more effectively address the challenges posed by dementias, ultimately improving patient outcomes.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company established in 2017 and headquartered in Mawson Lakes, Australia. The company specializes in the discovery and development of novel small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative drug candidates are designed to address difficult-to-treat diseases, with potential applications extending to various other health issues, including liver diseases. By focusing on these critical areas, Cincera Therapeutics strives to provide effective therapeutic solutions for patients suffering from complex medical conditions.

MycRx is a Melbourne-based drug development company focused on creating innovative treatments for cancer and antibiotics with novel mechanisms of action. Established in 2013 by a team with extensive experience in the pharmaceutical and biotechnology sectors, MycRx specializes in developing small molecule inhibitors that target the cMyc protein, which is implicated in over 50% of human cancers. The company leverages its proprietary “hit identification” technology to design these inhibitors, which aim to improve patient outcomes across various cancer types, including blood, melanoma, pancreatic, lung, breast, cervical, prostate, colon, stomach, bladder, and brain cancers. MycRx collaborates with prestigious institutions such as the Peter MacCallum Cancer Centre and CSIRO to advance its research and development efforts. The company operates as a virtual entity and has secured significant investment to support its mission.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergy. Founded in May 2015, the company emerged from the acquisition of intellectual property developed by Alfred Health and Monash University. Aravax's innovative approach involves proprietary technology that aims to reset the immune system, allowing patients to tolerate peanuts without experiencing allergic reactions during treatment. The company's focus is on creating vaccines that mitigate the risk of life-threatening responses to peanuts, providing a potential solution for individuals suffering from peanut allergies.

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

NRG Therapeutics is a drug discovery company established in 2018, specializing in therapeutic solutions aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and motor neuron disease. Founded by a team of professionals with extensive experience in the biotech and pharmaceutical sectors, the company focuses on developing brain-penetrant mitochondrial permeability transition pore inhibitors specifically for Parkinson's disease. NRG Therapeutics seeks to create innovative medicines that preserve mitochondrial function, thereby enabling effective treatment options for patients suffering from chronic neurodegenerative disorders.

Pheon Therapeutics is a London-based biotechnology company specializing in the development of Antibody-Drug Conjugates (ADCs) for challenging cancer types. Founded in 2022, the company focuses on creating a novel pipeline of next-generation ADCs designed to target solid tumors that are often resistant to existing treatments. Its lead program features a first-in-class ADC aimed at a unique target that is highly expressed in various hard-to-treat cancers. By advancing these innovative therapies, Pheon Therapeutics aims to provide effective treatment options for patients and healthcare providers facing the complexities of cancer management.

George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.

Denteric is a biotechnology company focused on developing a vaccine to combat periodontal diseases. Based on research from the University of Melbourne and supported by CSL Limited, Denteric's innovative platform targets virulence factors produced by the bacterium Porphyromonas gingivalis, which is associated with various dental diseases. The company's goal is to provide effective treatments that address both the disease itself and its complications, ultimately improving patient health outcomes in the field of dentistry.

OncoRes Medical is an early-stage medical device company based in Perth, Western Australia, focused on developing innovative imaging technology for breast cancer surgery. The company is creating a patent-protected intraoperative imaging tool that utilizes a novel combination of optical coherence tomography to enhance surgical accuracy and reduce complication rates. This technology provides real-time information to surgeons, assisting them in distinguishing between tumor and healthy tissue during procedures. OncoRes Medical collaborates with leading researchers from the University of Western Australia and the Harry Perkins Institute of Medical Research, as well as breast cancer surgeons within the Western Australian public health system. The company's goal is to transform the standard of care in breast cancer surgery through improved tissue microstructure assessment.

Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.

Perx Health is a digital care management program focused on enhancing treatment adherence among high-risk members with chronic conditions. Tailored specifically for clinically complex patients, the platform effectively manages various health issues, including diabetes and behavioral health, by employing a range of motivational techniques that address low health literacy. Perx Health's approach integrates reminders, education, and monitoring of medication regimens, while also utilizing gamification and rewards to encourage consistent medication adherence. This innovative strategy has resulted in a remarkable 90% adherence rate, leading to significant clinical improvements in metrics such as HbA1C and cholesterol control. Health plans utilizing Perx Health's services experience substantial cost savings and a high return on investment, underscoring the program's effectiveness in driving patient engagement and improving health outcomes.

Allay Therapeutics is focused on developing innovative solutions for post-surgical pain management, aiming to enhance patient recovery experiences. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutics. These products are designed to deliver targeted pain relief over extended periods, significantly surpassing the duration of existing pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical study for total knee arthroplasty surgeries. With a diverse team of entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics seeks to address the limitations of conventional pain management approaches, particularly the challenges associated with opioid use.

Currus Biologics is a biotechnology company focused on developing CAR-T cell therapies specifically aimed at treating solid tumor cancers. The company specializes in creating bispecific antigen-presenting and T-cell engagers to target and combat various cancer types, including breast, colon, pancreatic, and prostate cancers. By designing chimeric antigen receptors that can effectively kill cancer cells, Currus Biologics aims to provide innovative treatment solutions for patients with solid tumor indications.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company established in 2017 and headquartered in Mawson Lakes, Australia. The company specializes in the discovery and development of novel small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative drug candidates are designed to address difficult-to-treat diseases, with potential applications extending to various other health issues, including liver diseases. By focusing on these critical areas, Cincera Therapeutics strives to provide effective therapeutic solutions for patients suffering from complex medical conditions.

Glyscend Therapeutics is a biotechnology company focused on developing innovative treatments for metabolic diseases, particularly type 2 diabetes. Founded in 2014 and based in Baltimore, Maryland, Glyscend has created a non-invasive oral therapy designed to replicate the metabolic benefits of bariatric surgery. Their approach involves an ingestible intestinal coating that targets the duodenum, inhibiting key neurohormonal pathways to effectively manage glucose levels. This method allows patients to avoid the risks and complications associated with surgical procedures while providing healthcare professionals with a practical tool to treat type 2 diabetes rather than merely managing it. Glyscend is committed to enhancing patient outcomes by offering effective solutions that minimize side effects typically associated with diabetes treatments, such as weight gain and hypoglycemia.

George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.

Pathios Therapeutics is an early-stage biotech company based in Oxford, United Kingdom, focused on developing therapies for autoimmune diseases and cancer. Founded in 2017, the company specializes in creating small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to counteract the immunosuppressive effects of immune cells, such as tumor-associated macrophages, which are influenced by the acidic environment often found in tumors. By leveraging a deep scientific approach and human genetic insights, Pathios Therapeutics aims to generate novel therapeutics for advanced solid tumors and other unmet medical needs.

Denteric is a biotechnology company focused on developing a vaccine to combat periodontal diseases. Based on research from the University of Melbourne and supported by CSL Limited, Denteric's innovative platform targets virulence factors produced by the bacterium Porphyromonas gingivalis, which is associated with various dental diseases. The company's goal is to provide effective treatments that address both the disease itself and its complications, ultimately improving patient health outcomes in the field of dentistry.

EBR Systems, Inc., established in 2003 and based in Sunnyvale, California, specializes in developing implantable systems for wireless tissue stimulation. The company focuses on treating cardiac arrhythmias by creating devices that improve heart function through wireless cardiac stimulation. Its flagship product is the Wise CRT System, which employs proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart, enhancing its pumping efficiency and synchronizing rhythms.

Allay Therapeutics is focused on developing innovative solutions for post-surgical pain management, aiming to enhance patient recovery experiences. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutics. These products are designed to deliver targeted pain relief over extended periods, significantly surpassing the duration of existing pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical study for total knee arthroplasty surgeries. With a diverse team of entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics seeks to address the limitations of conventional pain management approaches, particularly the challenges associated with opioid use.

Q-Sera Pty Ltd is an Australian biotechnology company that specializes in the development of advanced blood collection tubes utilizing the coagulant properties of snake venom-derived proteins. The company has harnessed the potent clotting capabilities of components found in snake venom, particularly from species like the Australian Taipan, to create blood collection tubes that enable rapid production of high-quality serum. This innovative technology enhances laboratory efficiency, clinical diagnosis, and patient care by facilitating quicker coagulation of blood samples. Q-Sera's products are manufactured using modified cell lines and standard pharmaceutical processes, ensuring reliability and effectiveness in biochemical analysis of blood samples. The company's focus on leveraging unique natural resources positions it at the forefront of advancements in clinical and laboratory practices.

Certa Therapeutics, established in 2017 and headquartered in Melbourne, Australia, is a biotechnology company specializing in the development of precision medicines for fibrotic diseases, with a primary focus on kidney disorders. The company employs genetic analysis to identify patients at risk of developing kidney fibrosis, a precursor to end-stage kidney failure. Certa's drug pipeline targets a key receptor driving kidney fibrosis, aiming to halt or reverse the scarring process and prevent the need for dialysis or transplantation. Currently in the clinical stage, the company's mission is to transform the treatment landscape for fibrotic diseases by enabling early intervention and improving patient outcomes.

Global Kinetics Corporation Limited is a Melbourne-based company that specializes in mobile health technology aimed at managing patients with Parkinson's disease and other movement disorders. Founded in 2007, it focuses on the development of innovative solutions for monitoring, quantifying, and reporting the movement symptoms associated with neurological diseases. The company's flagship product, the PKG Data Logger, is a wrist-worn device designed to automatically capture movement data, thereby aiding healthcare professionals in diagnosing and treating movement disorders. The technology originated from research conducted by Professor Malcolm Horne and Dr. Rob Griffiths at the Florey Institute of Neuroscience & Mental Health, the largest neuroscience research team in Australia.

Okogen, Inc. is a biotechnology company based in Encinitas, California, focused on developing therapeutics for ocular infections affecting both adults and children. Founded in 2015, the company is dedicated to addressing unmet needs in the treatment of infectious ocular diseases, particularly where existing therapies are inadequate. Its lead candidate, OKG-0301, is a potent and broad-spectrum antiviral designed to function intracellularly, inhibiting viral replication to combat adenoviral infections as well as other viruses impacting the eye, such as herpes simplex virus and varicella-zoster virus. Okogen aims to reduce patient suffering, enhance quality of life, and protect vision through its innovative therapies.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company established in 2017 and headquartered in Mawson Lakes, Australia. The company specializes in the discovery and development of novel small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative drug candidates are designed to address difficult-to-treat diseases, with potential applications extending to various other health issues, including liver diseases. By focusing on these critical areas, Cincera Therapeutics strives to provide effective therapeutic solutions for patients suffering from complex medical conditions.

George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.

EBR Systems, Inc., established in 2003 and based in Sunnyvale, California, specializes in developing implantable systems for wireless tissue stimulation. The company focuses on treating cardiac arrhythmias by creating devices that improve heart function through wireless cardiac stimulation. Its flagship product is the Wise CRT System, which employs proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart, enhancing its pumping efficiency and synchronizing rhythms.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Elastagen is a clinical-stage medical company focused on developing products based on human protein tropoelastin, a vital component for tissues that require elasticity, such as skin and blood vessels. The company has created a synthetic version of elastin that mirrors the natural protein found in the human body, allowing for innovative applications in skin rejuvenation, scar remodeling, and tissue repair. Elastagen's offerings include injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic purposes, aimed at helping patients maintain skin elasticity and suppleness. Founded through the acquisition of intellectual property from research conducted by Prof Weiss at the University of Sydney, Elastagen has attracted significant investment from both Australian and international life science venture capital groups. Its operations have grown from Australia to include production facilities in Europe and clinical activities in the UK.

MetaBloQ is a biotechnology company dedicated to the development of innovative drugs aimed at treating various types of cancer, including triple-negative breast cancer, prostate cancer, and melanoma. The company focuses on targeting specific metabolic processes in cancer cells, allowing for therapies that minimize toxicity to healthy, non-cancerous cells. This approach aims to provide patients with safer, more effective, and better-tolerated treatment options in the fight against cancer.

Cardiora is a clinical stage biopharmaceutical company founded in 2015, dedicated to developing innovative treatments for patients suffering from end-stage heart failure, a condition marked by high mortality rates and frequent hospitalizations. The company is advancing its lead program, which is currently undergoing Phase Ib trials, while also completing IND enabling studies. Cardiora's primary focus is on an oral drug designed to prevent heart failure, aiming to enhance patient quality of life and reduce the rates of hospital re-admissions through its safety and efficacy profile. The company plans to initiate Phase II trials to further evaluate the drug's potential benefits.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergy. Founded in May 2015, the company emerged from the acquisition of intellectual property developed by Alfred Health and Monash University. Aravax's innovative approach involves proprietary technology that aims to reset the immune system, allowing patients to tolerate peanuts without experiencing allergic reactions during treatment. The company's focus is on creating vaccines that mitigate the risk of life-threatening responses to peanuts, providing a potential solution for individuals suffering from peanut allergies.

Global Kinetics Corporation Limited is a Melbourne-based company that specializes in mobile health technology aimed at managing patients with Parkinson's disease and other movement disorders. Founded in 2007, it focuses on the development of innovative solutions for monitoring, quantifying, and reporting the movement symptoms associated with neurological diseases. The company's flagship product, the PKG Data Logger, is a wrist-worn device designed to automatically capture movement data, thereby aiding healthcare professionals in diagnosing and treating movement disorders. The technology originated from research conducted by Professor Malcolm Horne and Dr. Rob Griffiths at the Florey Institute of Neuroscience & Mental Health, the largest neuroscience research team in Australia.

OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.

Solvanix is a biotechnology company focused on enhancing the stability and reducing the aggregation of fully human antibodies. Traditional monoclonal antibodies and their fragments often face challenges related to stability and aggregation, which can adversely affect manufacturability, formulation, and overall product quality. To address these issues, Solvanix has developed the proprietary StAbilize™ technology, which significantly boosts the stability of monoclonal antibodies, antibody fragments, and bi-specifics. The company collaborates with various biotech and pharmaceutical partners to improve their therapeutic antibodies and offers licenses for the use of its StAbilize™ technology, thereby contributing to advancements in antibody-based therapies.

MycRx is a Melbourne-based drug development company focused on creating innovative treatments for cancer and antibiotics with novel mechanisms of action. Established in 2013 by a team with extensive experience in the pharmaceutical and biotechnology sectors, MycRx specializes in developing small molecule inhibitors that target the cMyc protein, which is implicated in over 50% of human cancers. The company leverages its proprietary “hit identification” technology to design these inhibitors, which aim to improve patient outcomes across various cancer types, including blood, melanoma, pancreatic, lung, breast, cervical, prostate, colon, stomach, bladder, and brain cancers. MycRx collaborates with prestigious institutions such as the Peter MacCallum Cancer Centre and CSIRO to advance its research and development efforts. The company operates as a virtual entity and has secured significant investment to support its mission.

Heart Metabolics Limited is a pharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, making it harder for blood to leave the heart and often leading to heart failure or sudden death. With over 100,000 cases in the United States alone, HCM can be particularly severe in young adults and athletes. Current cardiovascular drugs do not help all patients, highlighting a significant medical need. Heart Metabolics is addressing this by developing perhexiline, an approved drug in Australia and New Zealand for angina, as a therapeutic for all types of HCM. The company plans to conduct clinical trials in the U.S. and seek FDA approval for perhexiline as an orphan drug, which it has already designated.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Protego Medical is a medical technology company focused on developing a device that enhances sternal protection during cardiac surgery. The device aims to address challenges associated with sternal bleeding and trauma that can occur during median sternotomy procedures. By improving surgical outcomes, Protego Medical's innovation offers potential clinical benefits for patients and financial savings for healthcare facilities, ultimately enabling cardiac surgeons to enhance their visibility and effectiveness during operations.

Auspherix, established in 2013 and headquartered in Stevenage, UK, specializes in the discovery and development of organogold-based antibiotics to combat serious, hard-to-treat, or potentially life-threatening infections. The company aims to advance these novel antibiotics through pre-clinical and clinical development, potentially for broad-spectrum use, by seeking further investment or industry partnerships.

PolyActiva is a biotechnology company specializing in the development of proprietary drug-polymer conjugate technology aimed at site-specific drug delivery. The company's innovative delivery platform is designed to facilitate the administration of therapeutic doses over extended periods from various medical device components, including ocular implants, intra-articular gel implants, and drug-eluting fibers. By creating biodegradable implants that sustain drug release, PolyActiva enhances patient outcomes and quality of life, particularly for individuals suffering from ophthalmic diseases such as glaucoma. This technology empowers healthcare organizations to provide more effective drug treatments tailored to the needs of patients.

G I Therapies is a Melbourne-based company founded in 2012 that specializes in developing non-invasive medical devices aimed at treating gastrointestinal motility disorders. The company's primary focus is on chronic constipation, a condition affecting both adults and children, as well as related issues such as irritable bowel syndrome with constipation and gastroparesis. By commercializing innovative technologies, G I Therapies seeks to enhance the quality of life for patients suffering from these disorders, providing effective solutions that promote better gastrointestinal health.

Q-Sera Pty Ltd is an Australian biotechnology company that specializes in the development of advanced blood collection tubes utilizing the coagulant properties of snake venom-derived proteins. The company has harnessed the potent clotting capabilities of components found in snake venom, particularly from species like the Australian Taipan, to create blood collection tubes that enable rapid production of high-quality serum. This innovative technology enhances laboratory efficiency, clinical diagnosis, and patient care by facilitating quicker coagulation of blood samples. Q-Sera's products are manufactured using modified cell lines and standard pharmaceutical processes, ensuring reliability and effectiveness in biochemical analysis of blood samples. The company's focus on leveraging unique natural resources positions it at the forefront of advancements in clinical and laboratory practices.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Vaxxas is a biotechnology company based in Brisbane, Australia, focused on developing a novel needle-free vaccination technology. Established in 2011, Vaxxas employs proprietary dry-coating technology that significantly reduces or eliminates the need for refrigeration during the storage and transportation of vaccines, thereby addressing logistical challenges associated with the cold chain. The company's innovative delivery system features an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This method allows for the direct deposition of vaccines among a dense population of immune cells in the skin, potentially transforming the global delivery of vaccines.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, specializing in the manufacture of portable point-of-care devices for both medical and veterinary markets. Established in 1998, the company is known for its flagship product, the SignosRT, which includes a bladder scanner that utilizes ultrasound technology to detect bladder presence and calculate volume, as well as a handheld ultrasound device designed to assist clinicians during examinations. Signostics aims to revolutionize healthcare practices by providing fast and affordable ultrasound solutions that can be easily integrated into clinical settings. The company has expanded its reach internationally, particularly entering the U.S. market in 2008, and offers its products through a network of distributors. Signostics is committed to enhancing medical practices across various fields, including internal medicine, family practice, and physical therapy.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, specializing in the manufacture of portable point-of-care devices for both medical and veterinary markets. Established in 1998, the company is known for its flagship product, the SignosRT, which includes a bladder scanner that utilizes ultrasound technology to detect bladder presence and calculate volume, as well as a handheld ultrasound device designed to assist clinicians during examinations. Signostics aims to revolutionize healthcare practices by providing fast and affordable ultrasound solutions that can be easily integrated into clinical settings. The company has expanded its reach internationally, particularly entering the U.S. market in 2008, and offers its products through a network of distributors. Signostics is committed to enhancing medical practices across various fields, including internal medicine, family practice, and physical therapy.

Fibrotech Therapeutics is a biopharmaceutical company based in Wonga Park, Australia, focused on developing novel drug candidates aimed at treating fibrosis associated with various chronic conditions. Established in 2006, the company is dedicated to addressing unmet medical needs in diseases such as diabetic nephropathy, kidney disorders, heart failure, pulmonary fibrosis, and arthritis. Through its innovative approach, Fibrotech Therapeutics seeks to provide effective therapeutic options for patients suffering from these debilitating conditions.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.